ProPhase Labs (PRPH)
(Delayed Data from NSDQ)
$0.77 USD
-0.01 (-1.03%)
Updated Nov 22, 2024 04:00 PM ET
After-Market: $0.77 0.00 (0.14%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
PRPH 0.77 -0.01(-1.03%)
Will PRPH be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for PRPH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PRPH
ProPhase Labs, Inc. (PRPH) Reports Q3 Loss, Tops Revenue Estimates
Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates
PRPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amneal Pharmaceuticals (AMRX) Surpasses Q3 Earnings and Revenue Estimates
Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates
Eli Lilly (LLY) Surpasses Q2 Earnings and Revenue Estimates
Other News for PRPH
ProPhase Labs Inc (PRPH) Q3 2024 Earnings Call Highlights: Strategic Launches and Financial ...
ProPhase Labs, Inc. (PRPH) Q3 2024 Earnings Call Transcript
ProPhase Labs: Strategic Moves for Future Growth
ProPhase Labs reports mixed Q3 results; initiates Q424 soft outlook
ProPhase Labs anticipates ‘significant sequential improvement’ in revenue in Q4